CXCL10 haplotypes and multiple sclerosis: Association and correlation with clinical course

European Journal of Neurology

Volumn 14, Issue 2, 2007, Pages 162-167

  Galimberti, D ^a   Scalabrini, D ^a   Fenoglio, C ^a   Comi, C ^b   De Riz, M ^a   Venturelli, E ^a   Lovati, C ^c   Mariani, C ^c   Monaco, F ^b   Bresolin, N ^a   Scarpini, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Clinical course; CXCL10; Haplotypes; Interferon inducible protein 10 polymorphisms; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; COURSE EVALUATION; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADOLESCENT; ADULT; AGED; CHEMOKINES, CXC; CYTOSINE; DISEASE PROGRESSION; EXONS; FEMALE; GENOTYPE; GUANINE; HAPLOTYPES; HETEROZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMINE;

EID: 33846459353     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01629.x     Document Type: Article

References (29)

1. Galimberti D, Bresolin N, Scarpini E. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Reviews of Neurotherapeutics 2004; 4: 439-453.
2. Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM. Synchronous Synthesis of α- and β-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. American Journal of Pathology 1997; 150: 617-630.
3. Sorensen L, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. Journal of Clinical Investigations 1999; 103: 807-815.
4. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. Journal of Neuroimmunology 2001; 115: 192-198.
5. Scarpini E, Galimberti D, Baron P, et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. Journal of the Neurological Sciences 2002; 195: 41-46.
6. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
7. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLADR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. American Journal of Human Genetics 2003; 72: 710-716.
8. Marrosu MG, Murru R, Murru MR, et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Human Molecular Genetics 2001; 10: 2907-2916.
9. Galimberti D, Fenoglio C, Clerici R, et al. E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. Journal of Neuroimmunology 2005; 165: 201-205.
10. Scalabrini D, Galimberti D, Fenoglio C, et al. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neuroscience Letters 2005; 388: 149-152.
11. Luster AD, Ravetch JV. Genomic characterization of a gamma-interferon- inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Molecular and Cellular Biology 1987; 7: 3723-3731.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS. Annals of Neurology 2001; 50: 121-127.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology 2005; 58: 840-846.
14. Lublin FD, Reingold SC for the National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis; results of an international survey. Neurology 1996; 46: 907-911.
15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. Journal of Neurology 2005; 252(Suppl. 3): III15-III20.
17. Fazekas F, Strasser-Fuchs S, Kollegger H, et al. Apolipoprotein E ε 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-857.
18. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Annals of Neurology 2004; 56: 303-306.
19. Fenoglio C, Galimberti D, Ban M, et al. SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis. Neuroscience Letters 2006; 394: 92-96.
20. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Multiple Sclerosis 2001; 7: 59-65.
21. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. Journal of Leukocyte Biology 1997; 61: 246-257.
22. Omari KM, John GR, Sealfon SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005; 128: 1003-1015.
23. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Current Opinion in Neurology 2006; 19: 248-254.
24. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. American Journal of Human Genetics 2002; 70: 708-717.
25. Cocco E, Sotgiu A, Costa G, et al. HLA-DR,DQ and APOE genotypes and gender influence in Sardinian primary progressive MS. Neurology 2005; 64: 564-566.
26. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. Journal of Neurology 2004; 251: 1208-1214.
27. Kwon JM, Goate AM. The candidate gene approach. Alcohol Research & Health 2000; 24: 164-168.
28. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069.
29. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. Journal of Neuroimmunology 2002; 123: 144-159.